American College of Radiology Imaging Network

Joseph A. Sparano, MD, FACP, driven by personal experience with cancer, has made significant contributions to breast cancer and HIV-associated cancer research. His pivotal TAILORx trial transformed breast cancer treatment, sparing many from unnecessary chemotherapy. Sparano also focuses on reducing racial disparities in cancer care and advancing treatment for HIV-associated cancers.

Fox Chase study finds 79% success in organ preservation for lower rectal cancer patients with node-negative tumors using neoadjuvant chemotherapy and local excision, with no local recurrences reported at 24 months median follow-up.

Extended follow-up data from the AMBASSADOR trial shows adjuvant pembrolizumab significantly improves disease-free survival in high-risk muscle-invasive urothelial carcinoma (29.6 vs 14.2 months). Benefits are consistent across PD-L1 status and lymph node involvement subgroups, though overall survival analysis is challenging due to unplanned crossover and patient withdrawals. Pembrolizumab's efficacy is seen in both lower and upper tract urothelial cancers, with common metastatic sites including lymph nodes, bone, liver, and lung. The data supports pembrolizumab as a therapeutic option and highlights the need for biomarkers to optimize patient selection.